secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-08-06T20:06:15+00:00
Accession:  0001193125-26-337964
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune Q2 net loss $32.2M; EVO756 AD Phase 2b data due Sept 2026
------------------------------------------------------------------

- Net loss of $32.2M for Q2 2026 vs $13.6M in Q2 2025; cash $288M as of June 30, 2026.
- EVO756 Phase 2b top-line data in moderate-to-severe atopic dermatitis expected September 2026.
- EVO756 migraine prophylaxis Phase 2b trial initiated; top-line data anticipated in 2027.
- Discontinued EVO756 development in chronic spontaneous urticaria after Phase 2b missed primary endpoint.
- EVO301 Phase 2a full positive data set in AD to be presented at upcoming medical conference; Phase 2b to start mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/0001193125-26-337964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/evmn-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-337964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer